ER+/PR− phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer

The loss of progesterone receptor (PR) often predicts worse biological behavior and prognosis in estrogen receptor-positive (ER +) breast cancer. However, the impact of PR status on inflammatory breast cancer (IBC) has not been studied. Therefore, the purpose of our study was to investigate the infl...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2024-01, Vol.14 (1), p.197-197, Article 197
Main Authors: Luo, Yunbo, Li, Qingyun, Fang, Jiang, Pan, Chaoying, Zhang, Lingxing, Xu, Xia, Qian, Shuangqiang, Zhao, Xiaobo, Hou, Lingmi
Format: Article
Language:English
Subjects:
631/67/1347
631/67/2329
Aggressive behavior
Breast cancer
Breast Neoplasms - pathology
Chemotherapy
Epidemiology
ErbB-2 protein
Estrogen receptors
Estrogens
Female
Genotype & phenotype
Humanities and Social Sciences
Humans
Inflammation
Inflammatory Breast Neoplasms
Lymph nodes
Medical prognosis
Metastases
Metastasis
Middle Aged
multidisciplinary
Phenotype
Phenotypes
Progesterone
Prognosis
Receptor, ErbB-2
Receptors, Estrogen
Receptors, Progesterone
Science
Science (multidisciplinary)
Survival
Survival analysis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The loss of progesterone receptor (PR) often predicts worse biological behavior and prognosis in estrogen receptor-positive (ER +) breast cancer. However, the impact of PR status on inflammatory breast cancer (IBC) has not been studied. Therefore, the purpose of our study was to investigate the influence of PR on IBC. Patients with ER+ and HER2-negative IBC were selected from the Surveillance, Epidemiology and End Results database. Pearson’s χ 2 test was used to compare the clinicopathological characteristics between patients with estrogen receptor-positive/progesterone receptor-positive (ER+/PR +) and patients with estrogen receptor-positive/progesterone receptor-negative (ER+/PR−). Univariate and multivariate analyses were performed to investigate the effects of PR status on the breast cancer-specific survival (BCSS) and overall survival (OS) in IBC. Overall, 1553 patients including 1157 (74.5%) patients with ER+/PR+ and 396 (25.5%) patients with ER+/PR− were analyzed in our study. The patients with ER+/PR− were more likely to be high histological grade (p 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-023-50755-4